AstraZeneca Vietnam has recently been recognised with two awards from the British Chamber of Commerce (BritCham). These mark the latest acknowledgement of the company’s effort in almost three decades of contribution to sustainable healthcare development in Vietnam.
While the company received the Great Service to Health Award, an award for Great Leadership was presented to Mr. Nitin Kapoor, Chairman and General Director of AstraZeneca Vietnam and Asia Area Frontier Markets; Vice President, International Vaccines & Immune Therapies.
The Great Service to Health Award recognised AstraZeneca Vietnam’s collective meaning contribution to uplift the local healthcare sector. While its innovative medicines are improving the lives of nearly 3 million Vietnamese patients struggling with non-communicable diseases (NCD) each year, the company’s COVID-19 vaccine, developed in partnership with the University of Oxford, was the first to be approved and used in Vietnam during the pandemic and has helped to protect millions of Vietnamese people. In order to protect high-risk and immunocompromised individuals against COVID-19, the company is also delivering a long-acting antibody combination that has been available in Vietnam since March this year.
Leading AstraZeneca’s ambitious strategy in Vietnam since 2018 has been Nitin — a British business leader with nearly 30 years of extensive experience across the finance, healthcare, and pharmaceutical industries in several continents. Under his steer, AstraZeneca Vietnam has become a market leader and a champion for public-private partnerships with the Vietnamese Government and healthcare partners to reduce both the infectious and non-communicable diseases burden and promote sustainability. Nitin has exemplified how visionary leadership can transform an organisation and make a meaningful impact on society.
Nitin said: “As a global biopharmaceutical company headquartered in the UK, AstraZeneca is honoured that our contributions to people and the society are recognised again by BritCham Vietnam. These awards are a great encouragement to us as we embark on a new journey of strategic, comprehensive partnership with Vietnam to bring quality healthcare and innovative medicines and vaccines to local communities. This recognition is for our leadership team, 500-plus employees in Vietnam and many other global colleagues who remain committed as ever to make health happen in Vietnam.”
In Vietnam, AstraZeneca has run several impactful programmes in collaboration with the Ministry of Health and healthcare partners to promote disease awareness, prevention and early detection. Amongst them are the Healthy Lung Programme to improve the quality of outpatient management of asthma, COPD and lung cancer; Young Health Programme to prevent and reduce NCD risk behaviours amongst young people; and CaReMe programme to transform the cardiovascular-renal-metabolic care ecosystem. AstraZeneca is also cooperating with the World Economic Forum, London School of Economics, and Health Strategy and Policy Institute – Vietnam Ministry of Health, in the Partnership for Health System Sustainability and Resilience (PHSSR), to study and recommend health policies that would help to holistically reinforce the Vietnamese health system well in preparing for future risks.
The latest awards add to the extensive list of recognition that AstraZeneca has received in its long history with Vietnam. In 2021, the Company received BritCham’s Great Contribution to Healthcare and 25+ Years Milestone award for its meaningful journey in Vietnam. The company also received the Minister of Health’s Certificate of Merit twice for excellent contributions to advancing cancer treatment (2019) and to Vietnam’s COVID-19 response (2020), amongst other industry awards.
The Great Awards programme is organised by BritCham to honour British companies, organisations, and individuals with significant contributions to the UK – Vietnam relationship for over 30 years in great sectors such as education, technology, banking, health & science.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Press release distributed by EloQ Communications.